Skip to content

FUSE MEDICAL, INC.: financial reference

Explore FUSE MEDICAL, INC. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2022-12-3119,762,581USD2023-04-14
Total liabilitiesAt date2022-12-3120,073,435USD2023-04-14
Stockholders equityAt date2022-12-31-310,854USD2023-04-14
Cash and cash equivalentsAt date2022-12-31147,854USD2023-04-14
Net income or loss2022-01-012022-12-313,098,113USD2023-04-14
Operating cash flow2022-01-012022-12-3134,799USD2023-04-14
Capital expenditure payments2020-01-012020-12-3120,757USD2022-03-31
Revenue2018-01-012018-12-3126,342,038USD2019-03-21
Contract revenue excluding tax2022-01-012022-12-3118,644,784USD2023-04-14
Financing cash flow2022-01-012022-12-31-440,135USD2023-04-14
Investing cash flow2020-01-012020-12-31-20,757USD2022-03-31
Retained earnings or deficitAt date2022-12-31-2,518,086USD2023-04-14
Basic weighted-average shares2022-01-012022-12-3170,321,566shares2023-04-14
Diluted weighted-average shares2022-01-012022-12-3177,860,418shares2023-04-14
Basic earnings per share2022-01-012022-12-310.04USD/shares2023-04-14
Diluted earnings per share2022-01-012022-12-310.04USD/shares2023-04-14
Income tax expense or benefit2022-01-012022-12-3123,655USD2023-04-14
Net property, plant and equipmentAt date2022-12-31709USD2023-04-14
Share-based compensation expense2022-01-012022-12-3122,852USD2023-04-14
Operating income or loss2022-01-012022-12-31-815,072USD2023-04-14
Current assetsAt date2022-12-3113,765,242USD2023-04-14
Interest expense2022-01-012022-12-31171,294USD2023-04-14
Current liabilitiesAt date2022-12-3112,387,737USD2023-04-14
Current accounts payableAt date2022-12-315,700,236USD2023-04-14
Goodwill carrying amountAt date2022-12-311,972,886USD2023-04-14
Net finite-lived intangible assetsAt date2022-12-31486,600USD2023-04-14
Net current accounts receivableAt date2022-12-313,996,860USD2023-04-14
Operating expenses2022-01-012022-12-3112,356,823USD2023-04-14
Net inventoryAt date2022-12-319,494,506USD2023-04-14
Gross profit2022-01-012022-12-3111,541,751USD2023-04-14
Cost of revenue2022-01-012022-12-317,103,033USD2023-04-14
Selling, general and administrative expense2022-01-012022-12-316,537,382USD2023-04-14

Inspect the source

Entity
FUSE MEDICAL, INC. / CIK 0000319016
Captured
2026-09-19T11:14:02.031Z
SEC response SHA-256
13d41024642d3becfdbc15fe6e31fdae11d4fa7a32679fcba6c1a612c57d756a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000319016.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))